Hypothyroidism/subclinical hypothyroidism and metabolic dysfunction-associated steatotic liver disease: advances in mechanism and treatment DOI Creative Commons

S L Pu,

Binbin Zhao,

Yuxuan Jiang

и другие.

Lipids in Health and Disease, Год журнала: 2025, Номер 24(1)

Опубликована: Фев. 27, 2025

Hypothyroidism is a risk factor for metabolic dysfunction-associated steatotic liver disease (MASLD) but it not clear whether subclinical hypothyroidism (SCH) increases the of MASLD and SCH patients with require treatment. In this study, we reviewed articles published in PubMed from 2013 to 2024 SCH/hypothyroidism as keywords. According studies retrieved, likelihood developing MASLD. Thyroid hormones influence energy metabolism storage adipose tissues, well fatty acid cholesterol transport liver. L-T4 replacement therapy reduces prevalence MASLD, especially severe or mild dyslipidemia. Recent showed that thyroid hormone analogues β receptor agonists obtained positive results treatment animal models clinical trials, Resmetirom has been approved by US. Food Drug Administration (FDA) under name Rezdiffra use conjunction dietary exercise regimens managing non-cirrhotic NASH adults moderate advanced fibrosis.

Язык: Английский

Ginsenoside, a potential natural product against liver diseases: a comprehensive review from molecular mechanisms to application DOI

Sitong Shang,

Haixia Yang, Linlin Qu

и другие.

Critical Reviews in Food Science and Nutrition, Год журнала: 2025, Номер unknown, С. 1 - 25

Опубликована: Янв. 15, 2025

Liver disease constitutes a significant cause of global mortality, with its pathogenesis being multifaceted. Identifying effective pharmacological and preventive strategies is imperative for liver protection. Ginsenosides, the major bioactive compounds found in ginseng, exhibit multiple activities including protection against liver-related diseases by mitigating fat accumulation inflammation, preventing hepatic fibrosis, exerting anti-hepatocarcinogenic effects. However, comprehensive overview elucidating regulatory pathways associated ginsenosides remains elusive. This review aims to consolidate molecular mechanisms through which different ameliorate distinct diseases, alongside pathogenic factors underlying ailments. Notably, Rb1 Rg1 demonstrate significantly treating fatty liver, hepatitis, CK Rh2 potent anti-hepatocellular carcinogenic Their these effects primarily involve modulation AMPK, NF-κB, TGF-β, NFR2, JNK, other pathways, thereby attenuating accumulation, inhibition stellate cell activation, promoting apoptosis hepatocellular carcinoma cells. Furthermore, it provides insights into safety profile current applications ginsenosides, facilitating their clinical development. Consequently, present promising prospects management, underscoring potential as valuable therapeutic agents this context.

Язык: Английский

Процитировано

0
Association of exposure to multiple volatile organic compounds with ultrasound-defined hepatic steatosis and fibrosis in the adult US population: NHANES 2017–2020 DOI Creative Commons
Wentao Shao, Pan Gong, Qihan Wang

и другие.

Frontiers in Public Health, Год журнала: 2025, Номер 12

Опубликована: Янв. 17, 2025

Volatile organic compounds (VOCs) are pervasive environmental pollutants known to impact human health, but their role in liver steatosis or fibrosis is not fully understood. This study investigates the association of urinary VOC mixtures with risk and U.S. adult population. Data 1854 adults from National Health Nutrition Examination Survey (NHANES) 2017.01 2020.03 were collected. Vibration Controlled Transient Elastography (VCTE) assessed hepatic via controlled attenuation parameter (CAP) stiffness measurement (LSM), respectively. The examined relationship between exposure biomarkers for 20 VOCs health outcomes using multivariate logistic regression Bayesian Kernel Machine Regression (BKMR) evaluate effects both individual mixed exposures. Multivariate analysis revealed that acrolein crotonaldehyde positively associated steatosis. Conversely, styrene, ethylbenzene, propylene oxide negatively Furthermore, 1,3-butadiene xylene fibrosis, while ethylbenzene was this condition. BKMR identified a significant positive joint effect on CAP. Notably, when other VOC-EBs held at median levels, exhibited linear correlations Ln CAP LSM, highlights potential hepatotoxic mixtures, particularly noting roles exacerbating fibrosis. These findings advocate further research explore mechanistic pathways conduct longitudinal studies establish causality enhance understanding VOCs' health.

Язык: Английский

Процитировано

0
The systemic Immune Inflammation index is a reliable and novel risk factor for metabolic dysfunction-associated fatty liver disease DOI
Mehmet Ali Kösekli, Gülali Aktaş

Current Medical Research and Opinion, Год журнала: 2025, Номер unknown, С. 1 - 8

Опубликована: Фев. 6, 2025

Background Metabolic dysfunction-associated fatty liver disease (MAFLD) can trigger inflammation, hepatocellular damage, cirrhosis, and carcinoma. There is a need for non-invasive, cost-effective diagnostic markers MAFLD, as current methods like biopsy are invasive. This study investigates the potential of systemic immune inflammation index (SII) useful tool in diagnosis MAFLD.Methods A cohort 806 individuals, including 426 with MAFLD 380 controls, was analyzed. SII values, along various biochemical inflammatory markers, were compared between groups.Results The group exhibited significantly higher which correlated key function. Median levels patients (581 (45-4553)) than that control (423 (112-2595)) (p < 0.001). showed moderate sensitivity (72%) specificity (56%) detecting MAFLD. Logistic regression analysis identified an independent risk factor unit increase increasing by 1.21 times.Conclusions These findings suggest could serve useful, noninvasive marker diagnosing monitoring warranting further longitudinal studies to explore its role progression treatment response.

Язык: Английский

Процитировано

0
Prophylactic effects of nutrition, dietary strategies, exercise, lifestyle and environment on nonalcoholic fatty liver disease DOI Creative Commons
Xiangyong Hao, Hao Song, Xin Su

и другие.

Annals of Medicine, Год журнала: 2025, Номер 57(1)

Опубликована: Фев. 12, 2025

Background Nonalcoholic fatty liver disease (NAFLD) is a chronic and its prevalence has risen sharply. However, whether nutrition, dietary strategies, exercise, lifestyle environment have preventive value for NAFLD remains unclear.

Язык: Английский

Процитировано

0
Hypothyroidism/subclinical hypothyroidism and metabolic dysfunction-associated steatotic liver disease: advances in mechanism and treatment DOI Creative Commons

S L Pu,

Binbin Zhao,

Yuxuan Jiang

и другие.

Lipids in Health and Disease, Год журнала: 2025, Номер 24(1)

Опубликована: Фев. 27, 2025

Hypothyroidism is a risk factor for metabolic dysfunction-associated steatotic liver disease (MASLD) but it not clear whether subclinical hypothyroidism (SCH) increases the of MASLD and SCH patients with require treatment. In this study, we reviewed articles published in PubMed from 2013 to 2024 SCH/hypothyroidism as keywords. According studies retrieved, likelihood developing MASLD. Thyroid hormones influence energy metabolism storage adipose tissues, well fatty acid cholesterol transport liver. L-T4 replacement therapy reduces prevalence MASLD, especially severe or mild dyslipidemia. Recent showed that thyroid hormone analogues β receptor agonists obtained positive results treatment animal models clinical trials, Resmetirom has been approved by US. Food Drug Administration (FDA) under name Rezdiffra use conjunction dietary exercise regimens managing non-cirrhotic NASH adults moderate advanced fibrosis.

Язык: Английский

Процитировано

0